Haleon plc (NYSE:HLN) Shares Sold by Cambiar Investors LLC

Cambiar Investors LLC decreased its holdings in Haleon plc (NYSE:HLN - Free Report) by 4.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,514,181 shares of the company's stock after selling 77,263 shares during the quarter. Cambiar Investors LLC's holdings in Haleon were worth $16,020,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Fortitude Family Office LLC purchased a new stake in Haleon in the third quarter valued at approximately $28,000. Cultivar Capital Inc. purchased a new stake in shares of Haleon during the 2nd quarter valued at $40,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Haleon during the 1st quarter valued at $43,000. Hexagon Capital Partners LLC increased its holdings in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock worth $55,000 after buying an additional 2,677 shares during the last quarter. Finally, BOKF NA raised its position in shares of Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock worth $58,000 after buying an additional 2,842 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Up 0.4 %

Shares of NYSE:HLN traded up $0.04 during mid-day trading on Friday, hitting $9.73. 4,814,313 shares of the company traded hands, compared to its average volume of 5,190,160. The firm's 50 day simple moving average is $10.23 and its 200 day simple moving average is $9.25. The firm has a market cap of $44.04 billion, a P/E ratio of 32.43, a PEG ratio of 2.87 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.80.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The firm had revenue of $3.50 billion for the quarter, compared to analysts' expectations of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the prior year, the business earned $0.08 EPS. On average, equities analysts anticipate that Haleon plc will post 0.46 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on HLN. Berenberg Bank started coverage on Haleon in a research note on Tuesday, August 6th. They set a "buy" rating for the company. The Goldman Sachs Group downgraded shares of Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research report on Friday, September 20th. Finally, UBS Group raised shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.